Treatment with Gleevec (Novartis), a selective inhibitor of several tyrosine kinases, including KIT, Bcr-Abl, and PDGF receptor ?, has been associated with depigmentation of skin of at least one chronic myelogenous leukemia patient (Raanani et al., 2002). Interestingly, treatment with Gleevec has also been reported to induce progressive repigmentation of gray hair in a small number of patients (Etienne et al., 2002). In addition to the hair depigmentation effects we have documented here with SU11248, we have also noted that the repigmented bands of patient hair evident during rest periods off SU11248 are sometimes darker than the original patient hair color (data not shown). The mechanistic basis underlying this phenomenon is as yet unknown and will require further study.
The above is abstract from TKI study is worried on if it could inhibit normal cell or stem cell repair or growth which in turn could affect our health or compromise normal cell repair or develope....
Any input ?
